Zacks Research Upgrades Pelthos Therapeutics (NYSEAMERICAN:PTHS) to Hold

Pelthos Therapeutics (NYSEAMERICAN:PTHS) was upgraded by Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued on Wednesday, Zacks reports.

Other equities analysts have also recently issued reports about the stock. Alliance Global Partners restated a “buy” rating on shares of Pelthos Therapeutics in a research report on Monday, October 26th. Oppenheimer reduced their price target on shares of Pelthos Therapeutics from $66.00 to $64.00 and set an “outperform” rating on the stock in a research report on Friday, August 14th. Finally, Lake Street Capital decreased their price objective on shares of Pelthos Therapeutics from $50.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday, October 12th. Seven research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $52.83.

Pelthos Therapeutics Stock Down 8.4%

Shares of NYSEAMERICAN PTHS opened at $9.30 on Wednesday. The company has a debt-to-equity ratio of 3.40, a quick ratio of 1.31 and a current ratio of 1.98. Pelthos Therapeutics has a 52 week low of $9.02 and a 52 week high of $37.50. The stock has a market capitalization of $35.62 million, a P/E ratio of -0.43 and a beta of 3.41. The stock’s fifty day moving average is $20.07 and its 200 day moving average is $23.91.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($6.62) earnings per share for the quarter. The firm had revenue of $15.60 million for the quarter. Pelthos Therapeutics had a negative return on equity of 204.71% and a negative net margin of 165.24%. Sell-side analysts forecast that Pelthos Therapeutics will post -15.22 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Pelthos Therapeutics stock. Pale Fire Capital SE grew its stake in Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) by 59.5% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 12,919 shares of the company’s stock after purchasing an additional 4,819 shares during the period. Pale Fire Capital SE owned about 0.38% of Pelthos Therapeutics worth $271,000 as of its most recent filing with the Securities and Exchange Commission. 77.96% of the stock is currently owned by institutional investors and hedge funds.

About Pelthos Therapeutics

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).